Please assess the completion status of the following clinical trial:

Trial Title: Ubiquinol (Reduced COQ10) for Patients With Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old~* Suspected or confirmed infection~* Presence of 2 or more systemic inflammatory response syndrome (SIRS) criteria~* Admission to the ICU~Exclusion Criteria:~* Under 18 years old~* Current CoQ10 supplementation~* Unable to receive enteral medications~* Would need a nasogastric or orogastric tube solely for the purposes of the study~* Pregnancy, incarceration, mentally disability~* Patient confirmed Comfort measures only, Do not resuscitate (DNR) and/or Do not intubate. Patients with DNR but intubated and being provided full care are eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
- Ubiquinol (Type: EXPERIMENTAL): Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).